Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging

  • Young Seok Cho
  • , Tae Jong Yoon
  • , Eue Soon Jang
  • , Kwan Soo Hong
  • , Shin Young Lee
  • , Ok Ran Kim
  • , Cheongsoo Park
  • , Yong Jin Kim
  • , Gyu Chul Yi
  • , Kiyuk Chang

Research output: Contribution to journalArticlepeer-review

94 Scopus citations

Abstract

Magneto-fluorescent silica nanoparticles were conjugated with cetuximab for the targeting and imaging of colon cancer. In this study, cetuximab-conjugated magneto-fluorescent nanoparticles (MFSN-Ctx) could specifically target colon cancer cells that expressed EGFR on their cell membranes, and specific fluorescence was detected. MFSN-Ctx produced significant MRI signal changes in a human colon cancer xenograft mouse model. Intravenous injection of MFSN-Ctx resulted in faster uptake as compared to intraperitoneal injection, indicating that MFSN-Ctx had different kinetic properties in tumors based on the method of injection. The local concentration of MFSN-Ctx in a tumor was amplified by the use of an external magnetic field. These results demonstrate the potential application of MFSN-Ctx for the detection of EGFR-expressing colon cancer using in vivo imaging approaches.

Original languageEnglish
Pages (from-to)63-71
Number of pages9
JournalCancer Letters
Volume299
Issue number1
DOIs
StatePublished - 18 Dec 2010

Bibliographical note

Funding Information:
This work was supported by a Korea Research Foundation to Eue-Soon Jang, a Korea Research Foundation Grant (KRF-2006-352-C00037) to Tae-Jong Yoon and a Korea Basic Science Institute Grant (T 27041) to Kwan Soo Hong.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cetuximab
  • Colon cancer
  • Molecular imaging
  • Nanoparticles

Fingerprint

Dive into the research topics of 'Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging'. Together they form a unique fingerprint.

Cite this